Sugi Predict

Sugi Predict / Compounds / SCHEMBL10366608

SCHEMBL10366608

SCHEMBL10366608

COC(=O)c1ccc(SCCCCl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.53
▸ ALDH1A1 P00352 1/20 0.53
▸ MAPT P10636 4/20 0.53
▸ RAB9A P51151 2/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ CA1 P00915 2/20 0.46
▸ CA2 P00918 2/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ CA12 O43570 1/20 0.46
▸ CA7 P43166 1/20 0.46
▸ CA9 Q16790 1/20 0.46
▸ CA14 Q9ULX7 1/20 0.46
▸ CYP4A11 Q02928 2/20 0.45
▸ LOXL2 Q9Y4K0 1/20 0.45
▸ CYP4F2 P78329 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ HDAC3 O15379 1/20 0.43
▸ HDAC4 P56524 1/20 0.43
▸ HDAC1 Q13547 1/20 0.43
▸ HDAC7 Q8WUI4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25224789 0.95 KMT2A (0.52) KMT2AALDH1A1MAPTRAB9AL3MBTL1
SCHEMBL10366613 0.90 ALDH1A1 (0.52) KMT2AALDH1A1MAPTRAB9AL3MBTL1
SCHEMBL22438891 0.86 THRA (0.58) KMT2AALDH1A1MAPTRAB9ACA1
SCHEMBL1796551 0.86 MAPT (0.47) KMT2AALDH1A1MAPTRAB9AL3MBTL1
SCHEMBL17517566 0.86 CYP4A11 (0.58) KMT2AALDH1A1MAPTRAB9AL3MBTL1
SCHEMBL9673198 0.85 CYP4A11 (0.58) KMT2AALDH1A1MAPTRAB9AL3MBTL1
SCHEMBL9038966 0.84 CA12 (0.51) KMT2AALDH1A1MAPTRAB9AL3MBTL1
SCHEMBL3712221 0.84 MAPT (0.49) KMT2AALDH1A1MAPTRAB9AL3MBTL1
SCHEMBL15191795 0.84 MAPT (0.49) KMT2AALDH1A1MAPTRAB9AL3MBTL1
SCHEMBL10498875 0.83 MAPT (0.49) KMT2AALDH1A1MAPTRAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4441033-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF Tango Therapeutics, Inc. (US) 2024-10-09 — — EP disclosed
CN-118715206-A Novel HDAC inhibitors and therapeutic uses thereof 探戈医药股份有限公司 2024-09-27 — — CN disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 — — US disclosed
WO-2023102162-A1 TGONOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-06-08 — — WO disclosed
WO-2023102162-A1 TGONOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-06-08 — — WO disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 — — US disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 — — US disclosed
US-8828996-B2 Morpholine-spirocyclic piperidine amides as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-09 — — US disclosed
EP-2686325-A1 MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS Vertex Pharmaceuticals Incorporated (US) 2014-01-22 — — EP disclosed
CN-103517910-A Morpholine-spirocyclic piperidine amides as modulators of ion channels VERTEX PHARMA 2014-01-15 — — CN disclosed
US-20120264749-A1 MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2012-10-18 — — US disclosed
WO-2012125613-A1 MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-09-20 — — WO disclosed
EP-0206662-B1 THIAZOLIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME Tanabe Seiyaku Co., Ltd. (JP) 1990-05-09 — — EP disclosed
US-4777178-A CARDIOTONIC AGENTS TANABE SEIYAKU CO., LTD. (JP) 1988-10-11 — — US disclosed
US-4689327-A N-substituted-2-[2-[2-(4-phenylpiperazine-1-yl)ethoxy]phenyl]-thiazolidine-3-carboxamides useful as cardiotonic agent TANABE SEIYAKU CO., LTD. (JP) 1987-08-25 — — US disclosed
EP-0206662-A1 Thiazolidine derivatives and process for preparing the same Tanabe Seiyaku Co., Ltd. (JP) 1986-12-30 — — EP disclosed
EP-0167355-A2 Thiazolidine derivative and processes for preparing the same Tanabe Seiyaku Co., Ltd. (JP) 1986-01-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF HDAC1, HDAC7, HDAC5 KMT2A 110/4885ALDH1A1 495/4885MAPT 2684/4885
US-20120264749-A1 MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS KCNJ2, TRPM5, KCNQ1 KMT2A 1876/4885ALDH1A1 1738/4885MAPT 1065/4885
US-12043607-B2 HDAC inhibitors and therapeutic use thereof HDAC1, HDAC7, HDAC5 KMT2A 97/4885ALDH1A1 477/4885MAPT 2829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.